Business Context and Reporting Period
This Form 8-K is filed by Xcyte Therapies, Inc. (not Bio Green Med Solution, Inc.) for the reporting period of December 1, 2005. The filing discloses the entry into a material definitive agreement regarding the company's principal executive offices in Seattle, Washington.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial data disclosed relates to the cost savings from a lease amendment:
- Monthly Rent Reduction: Approximately $35,000
- Monthly Operating Expense Reduction: Approximately $19,000
- Total Monthly Savings: Approximately $54,000
Material Changes
On December 1, 2005, Xcyte Therapies, Inc. entered into the Fifth Amendment to its Facility Lease with Alexandria Real Estate Equities, Inc. The material change involves the surrender of a portion of the leased premises at 1124 Columbia Street, Seattle. This action directly reduces the company's fixed occupancy costs effective immediately.
Outlook, Risks, and Management Commentary
Management commentary is limited to the summary of the lease amendment terms. The filing notes that the surrender of space is subject to the terms set forth in the original Lease dated June 21, 1999. There are no material relationships between the parties other than the lease agreement. The filing does not provide forward-looking guidance, risk factors, or discussion of contingencies beyond the lease terms.
Investor Verification Checklist
- Verify the exact square footage surrendered to confirm the proportional impact on total operating costs.
- Review the full text of the Fifth Amendment (Exhibit 10.1) for any termination fees or conditions attached to the surrender.
- Confirm the effective date of the rent and expense reductions to assess immediate cash flow impact.
- Check subsequent filings to ensure the company has not incurred unexpected costs related to the downsizing.